Showing 3051-3060 of 3545 results for "".
- New from Coppertone®: Whipped Sunscreenhttps://practicaldermatology.com/news/new-from-coppertone-whipped-sunscreen/2458309/COPPERTONE® is rolling out new Whipped formula sunscreens. The new formulas are available in the CLEARLYSheer® and WaterBABIES® Pure & Simple line. “For my patients, one of the biggest barriers to using everyday su
- Sun Pharma Introduces Leave Acne Behind Patient Initiativehttps://practicaldermatology.com/news/sun-pharma-introduces-leave-acne-behind-patient-initiative/2458310/Sun Pharma introudced a new initiative— “Leave Acne Behind™" — to educate patients and create awareness of severe recalcitrant nodular acne (SRNA). Sun Pharma reports that out of all of the prescription- treated acne cases today, 20 percent represent severe acne condi
- FDA Approves RHOFADE™ (Oxymetazoline Hydrochloride) Cream, 1% For Persistent Facial Erythema Associated With Rosaceahttps://practicaldermatology.com/news/fda-approves-rhofade-oxymetazoline-hydrochloride-cream-1-for-persistent-facial-erythema-associated-with-rosacea/2458315/The FDA has approved Allergan's RHOFADE™ cream for the topical treatment of persistent facial erythema associated with rosacea in adults. Approval was based on two clinical studies that evaluated the primary efficacy endpoint on day 29. Among the estimated 16 million aAmericans
- Encore Dermatology Inc. Launches TridesilonTM (desonide) Cream, 0.05% for ADhttps://practicaldermatology.com/news/encore-dermatology-inc-launches-tridesilontm-desonide-cream-005-for-ad/2458318/Encore Dermatology Inc. is rolling out TridesilonTM (desonide) Cream, 0.05% in a 60g tube for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Encore Dermatology Inc. licensed Tride
- Scarless Wound Healing Breakthrough: Researchers Turn Myofibroblasts in Wounds into Adipocyteshttps://practicaldermatology.com/news/scarless-wound-healing-breakthrough-researchers-turn-myofibroblasts-in-wounds-into-adipocytes/2458326/Scientists can now transform myofibroblasts found in wounds into adipocytes, paving the way toward scarless healing. Researchers began this work at the Perelman School of Medicine at the University of Pennsylvania, which led to a large-scale, multi-year study in connection with the P
- Sandoz Acquires AmLactin Brandhttps://practicaldermatology.com/news/sandoz-acquires-amlactin-brand/2458342/Sandoz today announced that it has acquired the AmLactin® family of skin care brands from Minnesota-based pharmaceutical company Upsher-Smith Laboratories, Inc.
- FDA Approved Eucrisa (Crisaborole) for ADhttps://practicaldermatology.com/news/fda-approved-eucrisa-crisaborole-for-ad/2458344/The U.S. Food and Drug Administration approved Eucrisa (crisaborole) ointment to treat mild-to-moderate eczema in patients two years of age and older. Eucrisa, applied topically twice daily, is a phosphodiesterase 4 (PDE-4) i
- AnaptysBio, Inc.'s IL-33-Blocker Cleared for Phase 2a Trials in AD, Peanut Allergyhttps://practicaldermatology.com/news/anaptysbio-incs-il-33-blocker-cleared-for-phase-2a-trials-in-ad-peanut-allergy/2458347/The United Kingdom Medicines and Healthcare Products Regulatory Agency has green lighted a Phase 2a clinical trial for AnaptysBio, Inc.’s ANB020 for the treatment of adults with moderate-to-severe atopic dermatitis. The United States Food and Drug Ad
- Can Vaseline Protect High-Risk Infants from Eczema? Study Says Yeshttps://practicaldermatology.com/news/can-vaseline-protect-high-risk-infants-from-eczema-study-says-yes/2458353/Applying low-cost moisturizers including petroleum jelly to a baby's skin for the first six months of his or her life is a cost-effective way to prevent eczema, finds a new study published in JAMA Pediatrics. Seven common moisturizers are cost effective in preventing eczema i
- Patient Enrollment Complete in Phase 3 Acne Trials for Minocycline Foam FMX101https://practicaldermatology.com/news/patient-enrollment-complete-in-phase-3-acne-trials-for-minocycline-foam-fmx101/2458357/Patient enrollment is now complete for two Phase 3 clinical trials evaluating the efficacy and safety of FMX101, a topical 4 percent minocycline foam for the treatment of moderate-to-severe acne, according to Foamix Pharmaceuticals Ltd. Foamix is con